search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
News


New blood test could be an early warning for childhood diabetes


A new type of blood test using lipids could make it easier to identify children at risk of complications around obesity including type two diabetes, liver and heart disease, say scientists. A new study from King’s College London published in Nature Medicine reveals a new relationship between lipids and diseases impacting metabolism in children, which could serve as an early warning system for conditions like liver disease. Using machines that test blood plasma in babies


that already exist in hospitals, the researchers suggest this could help doctors spot early signs of disease in children quicker and help them access the right treatment. The findings also contest the common idea that cholesterol is a leading cause of complications around obesity in children, identifying new lipid molecules which contribute to health risks like blood pressure but are not only correlated with a child’s weight. Lipids have traditionally been thought to be fatty acids in the body, either good or bad types of cholesterol or triglycerides – fats found in the bloodstream which are the most common in the human body. Recent studies from the same group of scientists have suggested that the picture is more complex. Using mass spectrometry, current evidence puts the types of different lipid present in the body in the thousands, each with separate functions. Taking a control sample of 1,300 children with obesity, the team assessed their lipids in blood. Afterwards 200 were put on the HOLBAEK-model for a year, a


lifestyle intervention for people with obesity popular in Denmark. Subsequent readings showed that among the intervention group, counts of lipids tied to diabetes risk, insulin resistance and blood pressure decreased, despite limited improvements in some children’s BMI.


Dr. Cristina Legido-Quigley, principal author,


said: “For decades, scientists have relied on a classification system for lipids that have split them into good and bad cholesterol, but now with a simple blood test we can assess a much broader range of lipid molecules that could serve as vital early warning signs for illness. In the future, this has the potential to be a new way to evaluate someone’s personal risk of disease and by studying how to change lipid molecules in the body, we could even prevent metabolic diseases like diabetes altogether.”


Sponsored by


A&E patients to get life-saving HIV and hepatitis tests


People aged 16 and over who receive routine blood tests when they attend Sheffield’s Northern General Hospital A&E department are to be tested for HIV, hepatitis B and hepatitis C, regardless of symptoms, as part of a new Government scheme, unless they choose to opt out. The routine testing will support earlier


detection and diagnosis of the blood borne viruses, saving lives and giving people access to the latest and most effective treatments (which can be curative in the case of hepatitis C). Opt-out blood borne virus (BBV) testing in


Emergency Departments has been a flagship initiative in other NHS A&E departments since 2022, helping to diagnose thousands of people with serious infections and saving thousands of lives. The scheme also supports the UK Action Plan to end all new HIV cases by 2030 through earlier identification and detection. Sheffield Teaching Hospitals NHS


Foundation Trust is one of 46 new sites to receive funding from the National Institute for Health and Care Research and NHS England to implement the scheme over the next 12 months. Posters will be available in A&E to inform patients about the testing.


Thousands more people with type 1 diabetes to get artificial pancreas


Tens of thousands of children and eligible adults living with type 1 diabetes across England are set to receive an ‘artificial pancreas’ thanks to cost- effective deals secured by the NHS with suppliers of the technology. These groundbreaking devices continually monitor the individual’s glucose levels and then automatically adjust the amount of insulin given to them through a pump. The NHS is a global leader in rolling out the cutting-edge technology to patients, with industry choosing the UK as a first-choice destination to launch the latest products in this space. Local NHS systems have been identifying eligible people living with type 1 diabetes who could benefit from the Hybrid Closed Loop (HCL) system – sometimes called an artificial pancreas – since April 2024, but thanks to these new price agreements and additional national funding, more patients are set to benefit this year. NHS England is providing £14.1m to local health systems to provide the technology to patients for the first year.


12 www.clinicalservicesjournal.com I November 2024


technology will mean some people living with type 1 diabetes will no longer need to inject themselves with insulin but rely on technology to receive this life saving medication. This can also help prevent life-threatening


There are currently around 270,000 people


living in England with type 1 diabetes. NHS England is encouraging all prescribing Trusts to review patients that are eligible for HCL and already using other diabetes technology including continuous glucose monitors (CGM) and insulin pumps. The new cost-effective prices are available to all eligible NHS patients benefitting from this technology, meaning the NHS will make considerable savings. The


hypoglycaemic and hyperglycaemia attacks, which can lead to seizures, coma or even death for people living with type 1 diabetes. Dr. Clare Hambling, NHS national clinical director for diabetes, said: “The technology behind the Hybrid Closed Loop systems will be completely lifechanging for many people living with type 1 diabetes, promising a better quality of life as well as clinical outcomes.” NICE recommends the devices should be rolled


out to children and young people under 19 with type 1 diabetes, pregnant women with type 1 diabetes, and adults who would benefit from this new technology to help manage high glucose levels. This will be a phased roll out over five years, as the


specialist clinical workforce in adult services build the skills in order to prescribe HCL systems.


click_and_photo - stock.adobe.com


angellodeco - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80